neurodegenerative disease

R&D

Biotech trends in COVID era: the pharmaphorum podcast

In episode 26 the pharmaphorum podcast hears from David Solomon, a 30-year life sciences industry veteran who recently took up the position of CEO at the Paris-based biopharmaceutical compa

News

Abstract blue DNA background. Medicine concept. 3D Rendering

Biogen teams up with gene-editing startup Scribe on ALS prog...

Scribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 million deal with Biogen.

News

Evotec and Celgene unite to drive forward oncology R&D

Evotec and Celgene have joined forces in a long-term strategic drug discovery and development partnership, to identify new therapeutics in oncology.

News

New HQ to be flagship for UK's dementia research

The UK is investing more in its ‘Grand Challenge’ to tackle dementia, with a £40 million investment in a dedicated headquarters for early-stage research.

Biotech trends in COVID era: the pharmaphorum podcast

Biogen teams up with gene-editing startup Scribe on ALS prog...

Evotec and Celgene unite to drive forward oncology R&D

New HQ to be flagship for UK's dementia research

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

neurodegenerative disease

Editor's Picks